[1]
|
Wu, Y.L., Zhong, W.Z., Li, L.Y., et al. (2007) Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. Journal of Thoracic Oncology, 2, 430-439.
https://doi.org/10.1097/01.JTO.0000268677.87496.4c
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.
https://doi.org/10.3322/caac.21332
|
[3]
|
何婧怡, 吴芳, 胡春宏. 第三代EGFR-TKIs治疗晚期非小细胞肺癌的耐药机制及应对策略研究进展[J]. 肿瘤防治研究, 2019, 46(10): 938-945.
|
[4]
|
中国临床肿瘤学会肿瘤生物标志物专家委员会, 《中国非小细胞肺癌患者EGFRT T790M基因突变检测专家共识》制定专家组. 中国非小细胞肺癌患者EGFR T790M基因突变检测专家共识[J]. 中华医学杂志, 2018, 98(32): 2544-2551.
|
[5]
|
Nagano, T., Tachihara, M. and Nishimura, Y. (2018) Mechanism of Resistance to Epidermal Growth Factor Receptor- Tyrosine Ki-nase Inhibitors and a Potential Treatment Strategy. Cells, 7, Article No. 212.
https://doi.org/10.3390/cells7110212
|
[6]
|
Lynch, T.J., Bell, D.W., Sordella, R., et al. (2020) Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. The New England Journal of Medicine, 350, 2129- 2139. https://doi.org/10.1056/NEJMoa040938
|
[7]
|
Mok, T.S., Wu, Y.L., Ahn, M.J., et al. (2017) Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England Journal of Medicine, 376, 629-640. https://doi.org/10.1056/NEJMoa1612674
|
[8]
|
Matikas, A., Mistri-otis, D., Georgoulias, V., et al. (2015) Current and Future Approaches in the Management of Non- Small-Cell Lung Cancer Patients with Resistance to EGFR TKIs. Clinical Lung Cancer, 16, 252-261.
https://doi.org/10.1016/j.cllc.2014.12.013
|
[9]
|
赵佳, 陈建业, 汤建才. 非小细胞肺癌吉非替尼耐药机制及治疗研究进展[J]. 中国现代应用药学, 2017, 34(6): 923-927.
|
[10]
|
Kobayashi, S., Boggon, T.J., Dayaram, T., et al. (2005) EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. The New England Journal of Medi-cine, 352, 786-792. https://doi.org/10.1056/NEJMoa044238
|
[11]
|
Lin, L. (2010) Mechanisms of Drug Resistance to Gefifinib and Erlotinib. International Journal of Oncology, 37, 734-736.
|
[12]
|
Park, K., Tan, E.H., O’Byrne, K., et al. (2016) Afatinib versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): A Phase 2B, Open-Label, Randomised Controlled Trial. The Lancet Oncology, 17, 577-589. https://doi.org/10.1016/S1470-2045(16)30033-X
|
[13]
|
侯冉, 胡泊, 史健. EGFR T790M突变在非小细胞肺癌中的研究进展[J]. 肿瘤防治研究, 2020, 47(6): 471-476.
|
[14]
|
Mukohara, T., Engelman, J.A., Hanna, N.H., et al. (2005) Differential Effects of Gefitinib and Cetuximab on Non- Small-Cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. Journal of the National Cancer Institute, 97, 1185-1194.
|
[15]
|
Okabe, T., Okamoto, I., Tsu-kioka, S., et al. (2009) Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non-Small Cell Lung Cancer Cell Lines with MET Amplification. Clinical Cancer Research, 15, 907-913.
|
[16]
|
Cho, B.C., Kim, H.J. and Sun, M.L. (2013). Abstract 5408: Enhancement of the Anti-Tumor Activity of Afatinib by Inhibition of Glycolysis in Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation. Cancer Re-search, 73, 5408. https://doi.org/10.1158/1538-7445.AM2013-5408
|
[17]
|
Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S.E., Cantarini, M., Barrett, J.C., Jänne, P.A. and Oxnard, G.R. (2015) Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M. Nature Medicine, 21, 560-562. https://doi.org/10.1038/nm.3854
|
[18]
|
Yu, H.A., Tian, S.K., Drilon, A.E., et al. (2015) Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M- Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncology, 1, 982-984. https://doi.org/10.1001/jamaoncol.2015.1066
|
[19]
|
Ercan, D., Choi, H.G., Yun, C.H., et al. (2015) EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhib-itors. Clinical Cancer Research, 21, 3913-3923. https://doi.org/10.1158/1078-0432.CCR-14-2789
|
[20]
|
Niederst, M.J., Hu, H., Mulvey, H.E., et al. (2015) The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clinical Cancer Research, 21, 3924-3933. https://doi.org/10.1158/1078-0432.CCR-15-0560
|
[21]
|
Mehlman, C., Cadranel, J., Rous-seau-Bussac, G., et al. (2019) Resistance Mechanisms to Osimertinib in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: A Multicentric Retrospective French Study. Lung Cancer, 137, 149-156.
https://doi.org/10.1016/j.lungcan.2019.09.019
|
[22]
|
Ortiz-Cuaran, S., Scheffler, M., Plenker, D., et al. (2016) Het-erogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Re-search, 22, 4837-4847.
https://doi.org/10.1158/1078-0432.CCR-15-1915
|
[23]
|
Xu, C., Wang, W., Zhu, Y., et al. (2019) Potential Re-sistance Mechanisms Using Next Generation Sequencing from Chinese EGFR T790M+ Non-Small Cell Lung Cancer Patients with Primary Resistance to Osimertinib: A Multicenter Study. Annals of Oncology, 30, II48. https://doi.org/10.1093/annonc/mdz063.012
|
[24]
|
刘超, 刘明辉, 刘红雨, 陈军. 奥希替尼在非小细胞肺癌中的耐药机制研究进展[J]. 中国医学前沿杂志(电子版), 2020, 12(7): 7-11.
|
[25]
|
Planchard, D., Loriot, Y., André, F., et al. (2015) EGFR-Independent Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M-Positive NSCLC Patients. Annals of Oncology, 26, 2073-2078.
https://doi.org/10.1093/annonc/mdv319
|
[26]
|
Alzahrani, A.S. (2019) PI3K/Akt/mTOR Inhibitors in Cancer: At the Bench and Bedside. Seminars in Cancer Biology, 59, 125-132. https://doi.org/10.1016/j.semcancer.2019.07.009
|
[27]
|
Kim, T.M., Song, A., Kim, D.W., et al. (2015) Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. Journal of Thoracic Oncology, 10, 1736-1744.
https://doi.org/10.1097/JTO.0000000000000688
|
[28]
|
Barnes, T.A., O’Kane, G.M., Vincent, M.D., et al. (2017) Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Frontiers in Oncology, 7, Article No. 113.
https://doi.org/10.3389/fonc.2017.00113
|
[29]
|
Le, X., Puri, S., Negrao, M.V., et al. (2018) Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy beyond Progres-sion in EGFR-Mutant NSCLC. Clinical Cancer Research, 24, 6195-6203. https://doi.org/10.1158/1078-0432.CCR-18-1542
|
[30]
|
Oxnard, G.R., Hu, Y., Mileham, K.F., et al. (2018) As-sessment of Resistance Mechanisms and Clinical Implications in Patients with EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncology, 4, 1527- 1534. https://doi.org/10.1001/jamaoncol.2018.2969
|
[31]
|
裴清华, 孙建立. 奥希替尼获得性耐药的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 105-112.
|
[32]
|
Lim, S.M., Kim, H.R., Cho, E.K., et al. (2016) Targeted Sequencing Identifies Genetic Alterations that Confer Primary Resistance to EGFR Tyrosine Kinase Inhibitor (Korean Lung Cancer Consortium). Oncotarget, 7, 36311-36320.
https://doi.org/10.18632/oncotarget.8904
|
[33]
|
Ercan, D., Xu, C., Yanagita, M., et al. (2012) Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors. Cancer Discovery, 2, 934-947. https://doi.org/10.1158/2159-8290.CD-12-0103
|
[34]
|
Minari, R., Bordi, P., Del Re, M., et al. (2018) Primary Re-sistance to Osimertinib Due to SCLC Transformation: Issue of T790M Determination on Liquid Re-Biopsy. Lung Can-cer, 115, 21-27.
https://doi.org/10.1016/j.lungcan.2017.11.011
|
[35]
|
Li, L., Wang, H., Li, C., et al. (2017) Transformation to Small-Cell Carcinoma as an Acquired Resistance Mechanism to AZD9291: A Case Report. Oncotarget, 8, 18609-18614. https://doi.org/10.18632/oncotarget.14506
|
[36]
|
Ham, J.S., Kim, S., Kim, H.K., et al. (2016) Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma during AZD9291 Treatment. Journal of Thorac-ic Oncology, 11, E1-E4.
https://doi.org/10.1016/j.jtho.2015.09.013
|
[37]
|
Taniguchi, Y., Horiuchi, H., Morikawa, T., et al. (2018) Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report. Case Reports in Oncology, 11, 323-329.
https://doi.org/10.1159/000489603
|
[38]
|
Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. (2011) Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 3, 75ra26.
https://doi.org/10.1126/scitranslmed.3002003
|
[39]
|
Lee, J.K., Lee, J., Kim, S., et al. (2017) Clonal History and Ge-netic Predictors of Transformation into Small-Cell Carcinomas from Lung Adenocarcinomas. Journal of Clinical Oncol-ogy, 35, 3065-3074.
https://doi.org/10.1200/JCO.2016.71.9096
|
[40]
|
Niederst, M.J., Sequist, L.V., Poirier, J.T., et al. (2015) RB Loss in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to Small-Cell Lung Cancer. Nature Communications, 6, Article No. 6377.
https://doi.org/10.1038/ncomms7377
|
[41]
|
Weng, C.H., Chen, L.Y., Lin, Y.C., et al. (2019) Epitheli-al-Mesenchymal Transition (EMT) beyond EGFR Mutations Per Se Is a Common Mechanism for Acquired Resistance to EGFR TKI. Oncogene, 38, 455-468.
https://doi.org/10.1038/s41388-018-0454-2
|
[42]
|
Ichihara, E., Westover, D., Meador, C.B., et al. (2017) SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research, 77, 2990-3000.
https://doi.org/10.1158/0008-5472.CAN-16-2300
|
[43]
|
Yochum, Z.A., Cades, J., Wang, H., et al. (2019) Targeting the EMT Transcription Factor TWIST1 Overcomes Resistance to EGFR Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. Oncogene, 38, 656-670.
https://doi.org/10.1038/s41388-018-0482-y
|
[44]
|
Wang, X., Zhou, L., Yin, J.C., et al. (2019) Lung Adenocarci-noma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Com-bination Therapy. Journal of Thoracic Oncology, 14, E85-E88. https://doi.org/10.1016/j.jtho.2019.01.015
|
[45]
|
Wang, Z. and Wu, Y.L. (2019) Re-Emerging C797S in Trans and Rechallenge of Osimertinib with Erlotinib. Journal of Thoracic Oncology, 14, E81-E82. https://doi.org/10.1016/j.jtho.2018.12.015
|
[46]
|
Shi, P., Oh, Y.T., Zhang, G., et al. (2016) Met Gene Amplification and Protein Hyperactivation Is a Mechanism of Resistance to Both First and Third Generation EGFR Inhibitors in Lung Cancer Treatment. Cancer Letters, 380, 494-504.
https://doi.org/10.1016/j.canlet.2016.07.021
|
[47]
|
Oxnard, G.R., Yang, J.C.H., Yu, H., et al. (2020) TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined with Selumetinib, Savolitinib, or Durvalumab in EGFR-Mutant Lung Cancer. Annals of Oncology, 31, 507-516.
https://doi.org/10.1016/j.annonc.2020.01.013
|
[48]
|
La Monica, S., Cretella, D., Bonelli, M., et al. (2017) Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines. Journal of Experimental & Clinical Cancer Research, 36, 174. https://doi.org/10.1186/s13046-017-0653-7
|
[49]
|
Nakatani, K., Yamaoka, T., Ohba, M., et al. (2019) KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Har-boring Exon 19 Deletion/T790M in EGFR. Molecular Cancer Therapeutics, 18, 112-126. https://doi.org/10.1158/1535-7163.MCT-18-0591
|
[50]
|
Yang, D., Dai, R., Zhang, Q., et al. (2018) Apatinib for Heavily Treated Patients with Non-Small Cell Lung Cancer: Report of a Case Series and Literature Review. Saudi Jour-nal of Biological Sciences, 25, 888-894.
https://doi.org/10.1016/j.sjbs.2017.12.011
|
[51]
|
Marcoux, N., Gettinger, S.N., O’Kane, G., et al. (2019) EGFR-Mutant Adenocarcinomas that Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology, 37, 278-285.
https://doi.org/10.1200/JCO.18.01585
|
[52]
|
Park, K., Haura, E.B., Leighl, N.B., et al. (2021) Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results from the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 39, 3391-3402. https://doi.org/10.1200/JCO.21.00662
|
[53]
|
Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., Wolf, B., Jones, B., Madrigal, J., Horton, J., Spiegel, M., Carroll, J., Gukasyan, J., Williams, T., Sauer, L., Wells, C., Hardy, A., Linares, P., Lim, C., Ma, L., Adame, C. and Ga-ron, E.B. (2018) A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Pa-tients with Advanced NSCLC. Journal of Thoracic Oncology, 13, 1138-1145. https://doi.org/10.1016/j.jtho.2018.03.035
|
[54]
|
Piotrowska, Z., Niederst, M.J., Karlovich, C.A., et al. (2015) Het-erogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 5, 713-722. https://doi.org/10.1158/2159-8290.CD-15-0399
|